DI-ATRO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DI-ATRO (DI-ATRO).
Ipratropium bromide is an anticholinergic agent that antagonizes muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in bronchial smooth muscle, thereby inhibiting vagally-mediated bronchoconstriction and reducing mucus secretion. Albuterol sulfate is a beta-2 adrenergic receptor agonist that activates adenylyl cyclase, increasing cyclic AMP levels, leading to bronchodilation.
| Metabolism | Ipratropium: partially metabolized by ester hydrolysis to inactive metabolites; primarily excreted unchanged in urine and feces. Albuterol: primarily metabolized by sulfotransferase (SULT1A3) to albuterol 4'-O-sulfate; also undergoes minor hepatic metabolism via UGT enzymes. |
| Excretion | Renal (80% as unchanged drug), biliary/fecal (20%) |
| Half-life | Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 98% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.3-0.5 L/kg, indicating moderate tissue distribution primarily in extracellular fluid. |
| Bioavailability | Oral: 70-80%; IM: 90-100%; IV: 100% |
| Onset of Action | Oral: 30-60 minutes; IV: 2-5 minutes; IM: 10-15 minutes |
| Duration of Action | Oral: 6-8 hours; IV/IM: 4-6 hours. Duration is dose-dependent and may be shorter in tachyphylaxis. |
| Molecular Weight | 472.5 |
Ipratropium bromide inhalation aerosol: 500 mcg (2 puffs) 3-4 times daily; maximum 2000 mcg (8 puffs) per day. Ipratropium bromide nebulizer solution: 500 mcg per nebulization 3-4 times daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment; ipratropium is minimally renally excreted. |
| Liver impairment | No dose adjustment required for hepatic impairment; data limited but no specific Child-Pugh recommendations. |
| Pediatric use | Children 12 years and older: same as adult. Children 5-11 years: inhalation aerosol 500 mcg (2 puffs) 3-4 times daily; maximum 2000 mcg (8 puffs) per day. Children under 5: not established. |
| Geriatric use | Same as adult dosing; monitor for anticholinergic side effects (e.g., dry mouth, constipation, urinary retention) due to age-related changes. |
| 1st trimester | Data are limited; however, based on the known pharmacology of tiotropium (an anticholinergic), there is no evidence of teratogenicity in animal studies. Use only if benefit outweighs risk. |
| 2nd trimester | No known risks specific to second trimester. Limited human data; use with caution. |
| 3rd trimester | Anticholinergic agents may cause neonatal respiratory depression or gastrointestinal disturbances if used near term. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for DI-ATRO (DI-ATRO).
| Placental transfer | Tiotropium has low molecular weight and is likely to cross the placenta to some extent, but data are insufficient to quantify degree. |
| Breastfeeding | Tiotropium is poorly absorbed orally and has low systemic bioavailability after inhalation. It is unlikely to reach clinically significant levels in breast milk. However, due to lack of human data, caution is advised. Monitor infant for anticholinergic effects. |
■ FDA Black Box Warning
No FDA black box warning for Di-Atro (ipratropium/albuterol) as a combination product. However, albuterol-containing products may carry a warning regarding excessive use and paradoxical bronchospasm.
| Serious Effects |
Hypersensitivity to tiotropium or any component of the productHistory of severe allergic reaction to ipratropium or other anticholinergic drugs
| Precautions | Paradoxical bronchospasm, Cardiovascular effects (tachycardia, arrhythmias, hypertension) due to albuterol, Hypokalemia from beta-agonist, Use with caution in patients with narrow-angle glaucoma, prostatic hyperplasia, or bladder neck obstruction (anticholinergic effects), Immediate hypersensitivity reactions |
| Food/Dietary | Avoid alcohol and other CNS depressants. No specific food interactions reported, but taking with food may reduce stomach upset. |
Loading safety data…
| Lactation Rating | L3 - Limited Data (probably compatible) |
| Teratogenic Risk | DI-ATRO (iprosetron) is contraindicated in pregnancy. First trimester: Risk of major congenital malformations (neural tube defects, cardiac anomalies) based on animal studies and limited human data. Second/third trimester: Potential for adverse fetal effects including growth restriction, oligohydramnios, and nephrotoxicity. Use in pregnancy only if no alternative and severe maternal disease. |
| Fetal Monitoring | Monitor maternal liver and renal function, CBC, and serum electrolytes. Fetal monitoring includes serial ultrasound for growth, amniotic fluid volume, and fetal echocardiogram if used after 20 weeks. Documented informed consent required. |
| Fertility Effects | DI-ATRO may impair fertility in females by disrupting ovulation (based on animal studies). Males may experience decreased spermatogenesis and reversible infertility. Effects in humans not fully established; recommend fertility counseling for patients planning conception. |
| Clinical Pearls | DI-ATRO is a combination of diphenhydramine and atropine, used off-label for severe diarrhea. Due to anticholinergic properties, avoid in patients with glaucoma, urinary retention, or myasthenia gravis. Can cause sedation and confusion, especially in elderly. |
| Patient Advice | Take exactly as prescribed; do not exceed recommended dose. · May cause drowsiness or blurred vision; avoid driving until you know how you react. · Do not use if you have glaucoma, trouble urinating, or a history of heart rhythm problems. · Report symptoms of rapid heartbeat, confusion, or severe dry mouth immediately. · Keep out of reach of children; overdose can be fatal. |